Immunotherapy in allogeneic hematopoietic stem cell transplantation - not just a case for effector cells

被引：12

作者：

Troeger, A

Meisel, R

Moritz, T

Dilloo, D

机构：

[1] Univ Dusseldorf, Klin Kinderhamatol Onkol & Immunol, D-40225 Dusseldorf, Germany

[2] Univ Duisburg Essen, Dept Internal Med Canc Res, W German Canc Ctr, Duisburg, Germany

来源：

BONE MARROW TRANSPLANTATION | 2005年 / 35卷 / Suppl 1期

关键词：

allogeneic hematopoietic stem cell transplantation; leukemia; vaccination; dendritic cells; mesenchymal stem cells;

D O I：

10.1038/sj.bmt.1704849

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The concept that in allogeneic hematopoietic stem cell transplantation (alloHSCT) the immune system plays a prominent role in the control of leukemic disease is supported by the clinical observation that immunological effector mechanisms contribute to the elimination of leukemic blasts. The failure to induce prolonged remission after alloHSCT has led to resurgent interest in complementing concepts of immune modulation to improve the antileukemic reponse. Whil e the general focus has been placed on manipulation of cytotoxic effector cell populations, we will explore the dual role of leukemia cells as both antigen-presenting and target cells and describe various vaccination strategies to facilitate a protective antileukemic immune response in this setting. In addition, we will introduce mesenchymal stem cells ( MSC) as another cell population recently recognized for their immunomodulatory properties. The potential benefits and hazards of MSC-cotransplantation in alloHSCT with regard to the graft versus leukemia (GvL) and the graft versus host (GvH) response will be discussed.

引用

页码：S59 / S64

页数：6

共 72 条

[41]

2-T

[42] Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation [J].

Meisel, R ;

Zibert, A ;

Laryea, M ;

Göbel, U ;

Däubener, W ;

Dilloo, D .

BLOOD, 2004, 103 (12) :4619-4621

[43]

MIWA H, 1992, LEUKEMIA, V6, P405

[44] Expression of the antiapoptosis gene survivin in human leukemia [J].

Mori, A ;

Wada, H ;

Nishimura, Y ;

Okamoto, T ;

Takemoto, Y ;

Kakishita, E .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 75 (02) :161-165

[45] Prevention of allogeneic fetal rejection by tryptophan catabolism [J].

Munn, DH ;

Zhou, M ;

Attwood, JT ;

Bondarev, I ;

Conway, SJ ;

Marshall, B ;

Brown, C ;

Mellor, AL .

SCIENCE, 1998, 281 (5380) :1191-1193

[46]

Murphy GP, 2000, PROSTATE, V43, P59, DOI 10.1002/(SICI)1097-0045(20000401)43:1<59::AID-PROS8>3.0.CO

[47]

2-D

[48] Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia [J].

Nakagawa, Y ;

Yamaguchi, S ;

Hasegawa, M ;

Nemoto, T ;

Inoue, M ;

Suzuki, K ;

Hirokawa, K ;

Kitagawa, M .

LEUKEMIA RESEARCH, 2004, 28 (05) :487-494

[49] Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells [J].

Nestle, FO ;

Alijagic, S ;

Gilliet, M ;

Sun, YS ;

Grabbe, S ;

Dummer, R ;

Burg, G ;

Schadendorf, D .

NATURE MEDICINE, 1998, 4 (03) :328-332

[50] Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression [J].

Oka, Y ;

Tsuboi, A ;

Taguchi, T ;

Osaki, T ;

Kyo, T ;

Nakajima, H ;

Elisseeva, OA ;

Oji, Y ;

Kawakami, M ;

Ikegame, K ;

Hosen, N ;

Yoshihara, S ;

Wu, F ;

Fujiki, F ;

Murakami, M ;

Masuda, T ;

Nishida, S ;

Shirakata, T ;

Nakatsuka, S ;

Sasaki, A ;

Udaka, K ;

Dohy, H ;

Aozasa, K ;

Noguchi, S ;

Kawase, L ;

Sugiyama, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (38) :13885-13890

← 1 2 3 4 5 6 7 8 →